Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026

NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.

Accesswire • 12 hours ago

Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance

A director for Protagonist Therapeutics sold 20,000 shares for a transaction value of approximately $1.7 million on Feb. 6, 2026. The transaction involved the exercise of stock options, after which the director held zero options.

The Motley Fool • Feb 16, 2026

Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes

Arturo Molina sold 9,514 directly on Jan. 20, 2026, generating a transaction value of approximately $784,700 at a reported price of $82.48 per share. This sale represented 8.91% of Dr. Molina's direct holdings, reducing his stake from 106,780 to 97,266 shares.

The Motley Fool • Feb 1, 2026

Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.

Accesswire • Jan 7, 2026

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood.

Business Wire • Jan 5, 2026

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide's efficacy and safety and demonstrate du.

Business Wire • Dec 6, 2025

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in September Rusfertide granted breakthrough designation for patients in Polycythemia Vera (PV) and the subject of four presentations including 52-week results of the VERIFY Phase 3 Study at ASH, the 67th Annual American Society of Hematology (ASH) meeting in December First patient dosed in the Phase 1 trial of PN-881, a first-in-class oral IL-17 peptide antagonist IND-enabling studies progressing as planned with triple-GLP/GIP/GCG agonists PN-477sc and PN-477o Oral hepcidin development candidate expected to be nominated by year end Cash, cash equivalents and marketable securities of $678.8 million as of September 30, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / November 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. "2025 continues to be a highly productive year with significant accomplishments in both partnered and wholly owned programs," said Dinesh V.

Accesswire • Nov 6, 2025

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.54 per share a year ago.

Zacks Investment Research • Nov 6, 2025

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, from December 6-9, 2025. ASH Presentation Details: Presenting Author: Andrew Kuykendall, MD (Moffitt Cancer Center) Publication Number: 81 Title: Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study Oral Session Name: 634.

Accesswire • Nov 3, 2025